Synonym
RC 1291; RC1291; RC-1291; RC 1291HCl; ONO7643; ONO-7643; ONO 7643; Anamorelin HCl
IUPAC/Chemical Name
2-amino-N-((R)-1-((R)-3-benzyl-3-(1,2,2-trimethylhydrazinecarbonyl)piperidin-1-yl)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-2-methylpropanamide hydrochloride
InChi Key
VFYAEUWJFGTGGO-GHTUPXNNSA-N
InChi Code
InChI=1S/C31H42N6O3.ClH/c1-30(2,32)28(39)34-26(18-23-20-33-25-15-10-9-14-24(23)25)27(38)37-17-11-16-31(21-37,29(40)36(5)35(3)4)19-22-12-7-6-8-13-22;/h6-10,12-15,20,26,33H,11,16-19,21,32H2,1-5H3,(H,34,39);1H/t26-,31-;/m1./s1
SMILES Code
CC(C)(N)C(N[C@H](CC1=CNC2=C1C=CC=C2)C(N3C[C@](C(N(C)N(C)C)=O)(CC4=CC=CC=C4)CCC3)=O)=O.[H]Cl.
Appearance
white to off-white solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in water or buffer.
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related:
861998-00-7 (Anamorelin HCl salt)
249921-19-5 (Anamorelin free base)
Biological target:
Anamorelin (RC-1291) hydrochloride is a potent ghrelin receptor agonist with EC50 value of 0.74 nM in the FLIPR assay.
In vitro activity:
In the FLIPR assay, ghrelin and ANAM showed significant agonist activity on the ghrelin receptor (Fig. 2a), with EC50 values of 0.67 nM (95 % confidence interval [CI] 0.60–0.76) and 0.74 nM (95 % CI 0.50–1.12), respectively. No significant antagonist activity was observed with ANAM at concentrations of up to 1,000 nM. In the binding experiments, ghrelin and ANAM bound to the ghrelin receptor (Fig. 2b) with a binding affinity constant (Ki) of 0.58 nM (95 % CI 0.51–0.66) and 0.70 nM (95 % CI 0.55–0.96), respectively.
Reference: J Cachexia Sarcopenia Muscle. 2014 Dec; 5(4): 329–337. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4248409/
In vivo activity:
Over the treatment period, animals administered anamorelin at 10 and 30 mg/kg/day showed a statistically significant increase in their percentage of mean BW (11.7 % ± 1.26 and 14.4 % ± 1.08, respectively) compared with controls (7.6 % ± 0.99; p < 0.01 versus 10 mg/kg and p < 0.001 versus 30 mg/kg). Mice administered 3 mg/kg anamorelin did not show a statistically significant increase in BW compared with control animals (9.1 % ± 0.97; p > 0.05).
Reference: Support Care Cancer. 2013; 21(9): 2409–2415. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3728440/
|
Solvent |
mg/mL |
mM |
| Solubility |
| DMSO |
28.0 |
48.01 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
583.16
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Pietra C, Takeda Y, Tazawa-Ogata N, Minami M, Yuanfeng X, Duus EM, Northrup R. Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile. J Cachexia Sarcopenia Muscle. 2014 Dec;5(4):329-37. doi: 10.1007/s13539-014-0159-5. Epub 2014 Sep 30. PMID: 25267366; PMCID: PMC4248409.
2. Northrup R, Kuroda K, Duus EM, Barnes SR, Cheatham L, Wiley T, Pietra C. Effect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model. Support Care Cancer. 2013 Sep;21(9):2409-15. doi: 10.1007/s00520-013-1800-0. Epub 2013 Apr 12. PMID: 23579947; PMCID: PMC3728440.
In vitro protocol:
1. Pietra C, Takeda Y, Tazawa-Ogata N, Minami M, Yuanfeng X, Duus EM, Northrup R. Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile. J Cachexia Sarcopenia Muscle. 2014 Dec;5(4):329-37. doi: 10.1007/s13539-014-0159-5. Epub 2014 Sep 30. PMID: 25267366; PMCID: PMC4248409.
In vivo protocol:
1. Pietra C, Takeda Y, Tazawa-Ogata N, Minami M, Yuanfeng X, Duus EM, Northrup R. Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile. J Cachexia Sarcopenia Muscle. 2014 Dec;5(4):329-37. doi: 10.1007/s13539-014-0159-5. Epub 2014 Sep 30. PMID: 25267366; PMCID: PMC4248409.
2. Northrup R, Kuroda K, Duus EM, Barnes SR, Cheatham L, Wiley T, Pietra C. Effect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model. Support Care Cancer. 2013 Sep;21(9):2409-15. doi: 10.1007/s00520-013-1800-0. Epub 2013 Apr 12. PMID: 23579947; PMCID: PMC3728440.
1: Zhang H, Garcia JM. Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC. Expert Opin Pharmacother. 2015 Jun;16(8):1245-53. doi: 10.1517/14656566.2015.1041500. Epub 2015 May 6. PubMed PMID: 25945893.
2: von Haehling S, Anker SD. Treatment of cachexia: An overview of recent developments. Int J Cardiol. 2015 Apr 1;184:736-42. doi: 10.1016/j.ijcard.2014.10.026. Epub 2014 Oct 16. PubMed PMID: 25804188.
3: Baracos VE. Skeletal muscle anabolism in patients with advanced cancer. Lancet Oncol. 2015 Jan;16(1):13-4. doi: 10.1016/S1470-2045(14)71185-4. Epub 2014 Dec 16. PubMed PMID: 25524803.
4: Garcia JM, Boccia RV, Graham CD, Yan Y, Duus EM, Allen S, Friend J. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. Lancet Oncol. 2015 Jan;16(1):108-16. doi: 10.1016/S1470-2045(14)71154-4. Epub 2014 Dec 16. PubMed PMID: 25524795.
5: von Haehling S, Anker SD. Treatment of cachexia: an overview of recent developments. J Am Med Dir Assoc. 2014 Dec;15(12):866-72. doi: 10.1016/j.jamda.2014.09.007. Epub 2014 Nov 20. PubMed PMID: 25455531.
6: von Haehling S, Anker SD. Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014. J Cachexia Sarcopenia Muscle. 2014 Dec;5(4):261-3. doi: 10.1007/s13539-014-0164-8. PubMed PMID: 25384990; PubMed Central PMCID: PMC4248411.
7: Salsman JM, Beaumont JL, Wortman K, Yan Y, Friend J, Cella D. Brief versions of the FACIT-fatigue and FAACT subscales for patients with non-small cell lung cancer cachexia. Support Care Cancer. 2015 May;23(5):1355-64. doi: 10.1007/s00520-014-2484-9. Epub 2014 Oct 29. PubMed PMID: 25351456; PubMed Central PMCID: PMC4376952.
8: Pietra C, Takeda Y, Tazawa-Ogata N, Minami M, Yuanfeng X, Duus EM, Northrup R. Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile. J Cachexia Sarcopenia Muscle. 2014 Dec;5(4):329-37. doi: 10.1007/s13539-014-0159-5. Epub 2014 Sep 30. PubMed PMID: 25267366; PubMed Central PMCID: PMC4248409.
9: Ebner N, Steinbeck L, Doehner W, Anker SD, von Haehling S. Highlights from the 7th Cachexia Conference: muscle wasting pathophysiological detection and novel treatment strategies. J Cachexia Sarcopenia Muscle. 2014 Mar;5(1):27-34. doi: 10.1007/s13539-014-0136-z. Epub 2014 Mar 5. PubMed PMID: 24595460; PubMed Central PMCID: PMC3953317.
10: Currow DC, Abernethy AP. Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome. Future Oncol. 2014 Apr;10(5):789-802. doi: 10.2217/fon.14.14. Epub 2014 Jan 28. PubMed PMID: 24472001.
